BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs

Journal of Cystic Fibrosis

Volumn 13, Issue 2, 2014, Pages 156-163

  Döring, Gerd ^a   Bragonzi, Alessandra ^b   Paroni, Moira ^b   Aktürk, Firdevs Fatma ^a   Cigana, Cristina ^b   Schmidt, Annika ^a   Gilpin, Deirdre ^c   Heyder, Susanne ^d   Born, Torsten ^e   Smaczny, Christina ^e   Kohlhäufl, Martin ^d   Wagner, Thomas O F ^e   Loebinger, Michael R ^f   Bilton, Diana ^f   Tunney, Michael M ^c   Elborn, J Stuart ^c   Pier, Gerald B ^g   Konstan, Michael W ^h   Ulrich, Martina ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d ROBERT BOSCH GMBH   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Anti inflammatory treatment; Cystic fibrosis; Pulmonary infection

Indexed keywords

AMELUBANT; AMIDINE; ANTIINFLAMMATORY AGENT; CARBAMIC ACID DERIVATIVE; LEUKOTRIENE B4 RECEPTOR;

ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTEREMIA; BLOOD; COMPLICATION; CYSTIC FIBROSIS; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN; INFLAMMATION; ISOLATION AND PURIFICATION; LEUKOCYTE COUNT; LUNG; MALE; METABOLISM; MICROBIOLOGY; MOUSE; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TREATMENT OUTCOME;

ADULT; AMIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTEREMIA; CARBAMATES; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LUNG; MALE; MICE; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECEPTORS, LEUKOTRIENE B4; TREATMENT OUTCOME;

EID: 84895067804     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.10.007     Document Type: Article

References (25)

1. Döring G., Ratjen F. Immunology of cystic fibrosis. Cystic fibrosis 2000, 69-80. Arnold Hammer, London, England. M.E. Hodson, D. Geddes, A. Bush (Eds.).
2. Ulrich M., Worlitzsch D., Viglio S., et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros 2010, 9:217-227.
3. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry 2005 annual data report 2006, Cystic Fibrosis Foundation, Bethesda.
4. Döring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012, 11:461-479. for the Consensus Study Group.
5. Döring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91. for the Consensus Study Group.
6. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994, 331:637-642. The Pulmozyme Study Group.
7. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007, 62:360-367.
8. Konstan M.W., Morgan W.J., Butler S.M., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007, 151:134-139.
9. McCormick J., Mehta G., Olesen H.V., Viviani L., Macek M., Mehta A. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010, 375:1007-1013.
10. McLaughlin F.J., Matthews W.J., Strieder D.J., et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983, 147:559-567.
11. Birke F.W., Meade C.J., Anderskewitz R., Speck G.A., Jennewein H.M. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther 2001, 297:458-466.
12. Ford-Hutchinson A.W., Bray M.A., Doig M.V., Shipley M.E., Smith M.J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286:264-265.
13. Yokomizo T., Izumi T., Chang K., Takuwa Y., Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
14. Back M., Bu D.X., Branstrom R., Sheikine Y., Yan Z.Q., Hansson G.K. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005, 102:17501-17506.
15. Serio K.J., Baker J.R., Ring W.L., Riddick C.A., Bigby T.D. Leukotriene B4 costimulates 5-lipoxygenase activity in neutrophils via increased 5-lipoxygenase translocation. Am J Physiol 1997, 272:C1329-C1334.
16. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237:1171-1176.
17. Konstan M.W., Walenga R.W., Hilliard K.A., Hilliard J.B. Leukotriene B4 is markedly elevated in epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993, 148:896-901.
18. Bragonzi A., Worlitzsch D., Timpert P., et al. Non-mucoid Pseudomonas aeruginosa expresses alginate in lungs of patients with cystic fibrosis and in a murine model. J Infect Dis 2005, 192:410-419.
19. Kendall M. A new measure of rank correlation. Biometrika 1938, 30:81-89.
20. Ehlers M.R.W. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbiol Infect 2000, 2:289-294.
21. Alten R., Gromnica-Ihle E., Pohl C., et al. Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis 2004, 63:170-176.
22. Driscoll K.E., Hassenbein D.G., Carter J., et al. Macrophage inflammatory proteins 1 and 2: expression by rat alveolar macrophages, fibroblasts, and epithelial cells and in rat lung after mineral dust exposure. Am Rev Respir Cell Mol Biol 1993, 8:311-318.
23. Tsai W.C., Hershenson M.B., Zhou Y., Sajjan U. Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res 2009, 58:491-501.
24. Koh A.Y., Priebe G.P., Ray C., Van Rooijen N., Pier G.B. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun 2009, 77:5300-5310.
25. Li Y., Karlin A., Loike J.D., Silverstein S.C. Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J Exp Med 2004, 200:613-622.